NRG Oncology has appointed a new Chair and Vice Chair to the organization’s Radiation Oncology Committee

The DREAMseq trial showed that starting treatment with immunotherapy, followed by targeted therapy if there is disease progression, is the preferred treatment approach for melanoma patients with a BRAF V600 tumor gene mutation

NRG-RTOG 1203 indicates that patients reported fewer adverse events following intensity-modulated radiotherapy treatment when compared to patients who received the standard 4-field pelvic radiotherapy; clinician-reported data showed no difference in symptoms for patients in the two treatment arms

Starting pembrolizumab before surgery instead of after significantly improved event-free survival for patients with stage 3-4 melanoma

Priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma

The Alliance for Clinical Trials in Oncology applauds the appointment of its Group Chair and President of the Alliance for Clinical Trials in Oncology Foundation Monica M. Bertagnolli, MD, FACS, FASCO, to serve as President Biden’s pick for Director of the National Cancer Institute

NRG Oncology has announced the appointment of several new Committee Chairs and Vice Chairs representing various areas of the organization

In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy

Long-term outcomes are now available from the E1912 trial for patients with chronic lymphocytic leukemia